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Abstract
This analysis presents a detailed defense of my epidemiologic research in the May 17, 2003 British
Medical Journal that found no significant relationship between environmental tobacco smoke (ETS)
and tobacco-related mortality. In order to defend the honesty and scientific integrity of my
research, I have identified and addressed in a detailed manner several unethical and erroneous
attacks on this research. Specifically, I have demonstrated that this research is not "fatally flawed,"
that I have not made "inappropriate use" of the underlying database, and that my findings agree with
other United States results on this relationship. My research suggests, contrary to popular claims,
that there is not a causal relationship between ETS and mortality in the U.S. responsible for 50,000
excess annual deaths, but rather there is a weak and inconsistent relationship. The popular claims
tend to damage the credibility of epidemiology.
In addition, I address the omission of my research from the 2006 Surgeon General's Report on
Involuntary Smoking and the inclusion of it in a massive U.S. Department of Justice racketeering
lawsuit. I refute erroneous statements made by powerful U.S. epidemiologists and activists about
me and my research and I defend the funding used to conduct this research. Finally, I compare many
aspect of ETS epidemiology in the U.S. with pseudoscience in the Soviet Union during the period
of Trofim Denisovich Lysenko. Overall, this paper is intended to defend legitimate research against
illegitimate criticism by those who have attempted to suppress and discredit it because it does not
support their ideological and political agendas. Hopefully, this defense will help other scientists
defend their legitimate research and combat "Lysenko pseudoscience."
Background
This analysis presents a detailed response to the extensive
attacks that have been made on my epidemiologic
research in the May 17, 2003 British Medical Journal, "Envi-
ronmental tobacco smoke and tobacco related mortality
in a prospective study of Californians during 1960–98"
[1]. I seek to defend the honesty and scientific integrity of
my research and I directly respond to my most powerful
critics, who have attempted to suppress and discredit find-
ings that do not support their ideological and political
agendas. To put a historical perspective on the tactics that
have been used against me, I conclude by making an anal-
ogy with the pseudoscientific practices of Trofim Deniso-
vich Lysenko [2]. Hopefully, my defense will encourage
and/or help other honest scientists to defend their
research against unwarranted and illegitimate criticism.
This analysis deals with several important elements of the
attacks, with a primary focus on the epidemiologic issues
involved. Additional elements of the attack are mentioned
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briefly in this analysis and are presented in detail on my
Scientific Integrity Institute website, under 'Research
Defense' [3]. Being attacked for publishing unpopular sci-
entific findings is not unique to me or my research. How-
ever, the nature and scope of the attacks to which I have
been subjected is quite unusual and needs to be docu-
mented and addressed.
Being able to distinguish between real and implied scien-
tific misconduct is important to the integrity of science in
general and to the integrity of individual scientists in par-
ticular. Falsely accusing an honest scientist of scientific
misconduct is just as wrong as scientific misconduct itself.
Implying that an honest scientist has committed scientific
misconduct because he has published unpopular findings
or has used an unpopular funding source is wrong and
falls under the category of "scientific McCarthyism" [4].
Analysis
Background on BMJ Paper
I begin with a presentation of the background necessary to
understand the issues involved with the May 17, 2003
British Medical Journal (BMJ) paper that I wrote with Dr.
Geoffrey C. Kabat [1]. This account primarily involves me
and thus is written in the first person, but it also refers to
Kabat where appropriate and not otherwise noted. Our
paper found no relationship between environmental
tobacco smoke (ETS) and tobacco-related mortality in a
prospective study of Californians during 1960–1998, with
some associations slightly below the null and some
slightly above the null, but none statistically different
from the null. It concluded, "The association between
exposure to environmental tobacco smoke and coronary
heart disease and lung cancer may be considerably weaker
than generally believed." It is the largest (in terms of sta-
tistical power), most detailed (in terms of results pre-
sented), and most transparent (in terms of information
about its conduct) epidemiologic paper on ETS and mor-
tality ever published in a major medical journal.
The study is based on the California (CA) portion of the
original 25-state Cancer Prevention Study (CPS I) [1]. CA
CPS I was begun by the American Cancer Society (ACS) in
1959 and has been conducted at UCLA by me since 1991.
Kabat and I are both well qualified epidemiologists who
have had long and successful careers dating back to the
1970s, as can be confirmed by examining our epidemio-
logic publications on PubMed. Our paper was deemed to
be scientifically sound and worthy of publication after
being peer reviewed by two distinguished epidemiolo-
gists, a BMJ statistician, and a BMJ editorial committee.
The details of the entire peer review process and the names
of all the individuals involved in the review process are
available online as the "Prepublication history" [5]. The
paper was subjected to the same review process and selec-
tion criteria as other papers submitted to the BMJ, which
publishes less than 10% of the total submissions it
receives [6].
In the interest of transparency and full disclosure, the
paper included the following detailed statements about
the funding history of the study and the competing inter-
ests of the authors: "Funding: The American Cancer Soci-
ety initiated CPS I in 1959, conducted follow up until
1972, and has maintained the original database. Extended
follow up until 1997 was conducted at the University of
California at Los Angeles with initial support from the
Tobacco-Related Disease Research Program, a University
of California research organisation funded by the Propo-
sition 99 cigarette surtax. After continuing support from
the Tobacco-Related Disease Research Program was
denied, follow up through 1999 and data analysis were
conducted at University of California at Los Angeles with
support from the Center for Indoor Air Research, a 1988–
99 research organisation that received funding primarily
from US tobacco companies. Competing interests: In
recent years JEE has received funds originating from the
tobacco industry for his tobacco related epidemiological
research because it has been impossible for him to obtain
equivalent funds from other sources. GCK never received
funds originating from the tobacco industry until last
year, when he conducted an epidemiological review for a
law firm which has several tobacco companies as clients.
He has served as a consultant to the University of Califor-
nia at Los Angeles for this paper. JEE and GCK have no
other competing interests. They are both lifelong non-
smokers whose primary interest is an accurate determina-
tion of the health effects of tobacco." [1].
Initial Attacks on BMJ paper
Even though our paper satisfied (and in many ways
exceeded) the accepted standards of epidemiologic analy-
sis and writing, it was immediately attacked by people
who did not like the results we reported. Beginning in the
days before May 17, 2003, our BMJ paper was subjected to
a large-scale ad hominem attack. Since our honesty or sci-
entific integrity had never previously been questioned,
such an attack seemed to us to be quite implausible and
indeed incredible. Based on what I have learned since May
2003, I describe the key elements of this attack in order to
expose the tactics that have been used in an attempt to dis-
credit and silence legitimate epidemiologic research.
Additional details are presented on my Scientific Integrity
Institute website [3]. The attack has been largely due to the
fact that we published politically incorrect null findings
from a long-term study primarily funded by the ACS, but
completed with a research award to UCLA from the
Center for Indoor Air Research (CIAR), a now-defunct
tobacco-industry funded research organization.Epidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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On May 9, 2003 I learned that our paper was to be pub-
lished in the May 17, 2003 BMJ and that an embargoed
BMJ press release was to be issued on May 13, 2003. The
strict publication/broadcast embargo regarding our paper
was to last until 00:01 hours (UK time) on May 16, 2003,
which was 19:01 (7:01 PM) EDT on May 15, 2003 in Flor-
ida and 16:01 (4:01 PM) PDT on May 15, 2003 in Califor-
nia. During this period, the ACS was informed of our
forthcoming paper and the press embargo. The ACS then
prepared its own press release entitled "American Cancer
Society Condemns Tobacco Industry Study for Inaccurate
Use of Data." The May 14, 2003 version of the ACS press
release was inserted into a May 15, 2003 email message of
Stanton A. Glantz, Ph.D., Professor of Medicine at the
University of California, San Francisco (UCSF). Glantz
send out this message worldwide to his UCSF listserv
before the press embargo ended [7]. The official May 15,
2003 version of the ACS press release, which adhered to
the press embargo, was issued in a separate PDF form [8].
Then it was permanently posted on the ACS web site in a
slightly different format [9].
The instantaneous attack on our paper appears to have
been a coordinated effort, primarily organized by the ACS
and Glantz. Glantz is a well-known anti-smoking activist
who has worked closely with the ACS for many years [10].
As part of this coordinated effort, Glantz organized a May
15, 2003 Miami, Florida press conference involving a
panel of "international experts" in order to "debunk" our
"Marry a Smoker, Get Less Cancer" study before the press
embargo ended [11]. At the time of the ACS press release
and the Miami press conference, neither the ACS, Glantz,
or the other Miami "experts" had access to the full ten-
page version of our paper, let alone time to read it and
carefully analyze it. The full version of our paper was not
posted on the BMJ website until the press embargo lifted
at 7:01 PM EDT on May 15, 2003 [1]. The only version
available when the embargoed BMJ  press release was
issued on May 13, 2003 was the abridged five-page paper
that appears in the print version of the BMJ [12]. Obvi-
ously, these critics chose to hastily write a press release
and hold a press conference based on limited informa-
tion. They did not have the integrity or objectivity to read
our full ten-page paper or to contact the authors before
beginning their attack, which included erroneous claims
about the paper's content and quality.
The ACS press release was authored by Michael J. Thun,
M.D., ACS Vice President, Epidemiology and Surveillance
Research, and Harmon J. Eyre, M.D., ACS Chief Medical
Officer. This press release makes several entirely false
statements about the study, such as:
1) "Tobacco Industry Study" was "Part of Organized Effort
to Confuse Public About Secondhand Smoke"
2) "Society researchers repeatedly advised Dr. Enstrom
that using CPS-I data to study the effects of secondhand
smoke would lead to unreliable results"
3) "this study is neither reliable nor independent"
4) "The study suffers from a critical design flaw: the inabil-
ity to distinguish people who were exposed to second-
hand smoke from those who were not"
5) "exposure to secondhand smoke was so pervasive [in
1959] that virtually everyone was exposed to ETS, whether
or not they were married to a smoker".
Further distracting from the actual content of the study
and the legitimacy of the analysis, the press release added
a number of out of context quotes from formerly confi-
dential tobacco industry documents that had nothing to
do with the conduct, analysis, or publication of the study.
For the past several years these documents have been
available online from the Legacy Tobacco Documents
Library at UCSF [13], which was established by Glantz
[14]. These documents are also available at other online
tobacco document libraries [15]. As shown above, my
tobacco industry funding and competing interests were
clearly and accurately described in more than 200 words
in the BMJ paper [1]. However, in order to raise doubts
about my honesty and scientific integrity, the ACS made a
great effort to locate and extract selective quotes from the
professional correspondence I have had with the tobacco
industry during my career. This ad hominem attack
diverted attention from the paper itself and obscured its
contribution to the body of epidemiologic evidence
regarding the lethality of ETS.
A major element of the attack included the submission to
the BMJ website of over 150 mostly negative electronic let-
ters, known as "rapid responses" (rrs) [16]. The overall
content and nature of these rrs was summarized by a BMJ
associate editor in an August 30, 2003 letter [17]. Particu-
larly troubling are May 19 and 20, 2003 rrs by Thun
[18,19], a May 30, 2003 rr by Thun and 13 other members
of the International Agency for Research on Cancer
(IARC) Working Group on tobacco smoke [20], and a
August 19, 2003 rr by Drs. Phillip S. Gardiner, Charles
Gruder, and Francisco Buchting of the University of Cali-
fornia Office of the President [21]. None of the authors of
these criticisms ever contacted us for a clarification of any
aspect of our BMJ paper or our contacts with the tobacco
industry before posting their rrs.
Most of the press coverage of the study was muted or
equivocal because of the issues raised by the ACS criticism
of the paper. Typical of this type of newspaper coverage
was the May 16, 2003 Los Angeles Times article on pageEpidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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A26, "Study Downplays the Health Risks From Second-
hand Smoke." This article concludes with the following
quote from Dr. Jonathan Samet, Professor and Chair of
Epidemiology at the Johns Hopkins University Bloomb-
erg School of Public Health: "We have one very flawed
study that does not find an association. It flies in the face
of so much evidence and so much scientific understand-
ing that it just doesn't contribute." [22].
Supportive Commentary on the BMJ Paper
A supportive press account appeared in the May 18, 2003
Sunday Telegraph newspaper article, "Warning: the health
police can seriously addle your brain," by Robert Mat-
thews [23]. The article noted, "More than any other health
debate, the question of whether smokers kill others as
well as themselves is engulfed in a smog of political cor-
rectness and dubious science." Other supportive com-
mentaries also appeared. Michael Fumento, a Senior
Fellow at the Hudson Institute, wrote a September 11,
2003 syndicated column, "Second-hand Smoke is Harm-
ful to Science" [24]. Elizabeth Whelan, Sc.D., President of
the American Council on Science and Health (ACSH),
wrote an August 13, 2004 ACSH column entitled "Ameri-
can Cancer Society a Danger to Science?" [25]. Michael
Fitzpatrick, M.D., a general practice physician in London,
wrote a November 15, 2004 Spiked commentary entitled
"We have ways of making you stop smoking." [26]. These
commentaries put our BMJ  findings in context and
described the excesses of the anti-smoking critics who
attacked us.
Two sociologists, Drs. Sheldon Ungar and Dennis Bray,
noticed the rrs and the other media coverage of my paper
and described the phenomena that they observed in their
own January 2005 paper [27]. They described in detail the
"efforts to prevent the making of specific scientific claims
in any or all of the arenas in which these claims are typi-
cally reported or circulated" as they related to my BMJ
paper. Their "results suggest that the public consensus
about the negative effects of passive smoke is so strong
that it has become part of a regime of truth that cannot be
intelligibly questioned." Given all the controversies
involving other epidemiologic risk factors, such as, hor-
mone replacement therapy, air pollution, and vitamin
supplements, this state of affairs regarding ETS is quite
amazing. Indeed, the evidence regarding the lethality of
ETS is not "a regime of truth," but collection of weak
results that have turned into a "causal" relationship by
carefully chosen committees. As I will discuss later, the
epidemiologic evidence on this subject has changed in
recent years and needs to be completely and objectively
reassessed in order to reach a valid conclusion.
Authors and Editor Defend the BMJ Paper
The attack described above was quite startling to me as
someone whose honesty and scientific integrity had never
been questioned during the 33-year period from July
1970, when I received my Ph.D. [28], until May 2003 [1].
It was also startling that the attack was initiated by the
ACS, the very organization that had given me the original
California Cancer Prevention Study (CA CPS I) data in
1991 upon which the BMJ study was based. Kabat and I
dealt with some of the initial controversy by responding
to specific criticisms in our August 30, 2003 BMJ letter
[29] and in our January 31, 2004 Lancet letter [30]. In par-
ticular, in these letters we refuted the five false ACS state-
ments shown above:
1) This was not a "Tobacco Industry Study," but rather a
UCLA study conducted by two qualified epidemiologists
with ACS cooperation up until publication of the BMJ
paper. This was not "Part of Organized Effort to Confuse
Public About Secondhand Smoke", but rather it was an
accurate representation of the results of one study. The
tobacco industry played no role in the conduct, writing, or
publication of the paper, and did not even know it was
being published until it appeared.
2) It is a complete fabrication that "Society researchers
repeatedly advised Dr. Enstrom that using CPS-I data to
study the effects of secondhand smoke would lead to
unreliable results." Indeed, the ACS Vice President for Epi-
demiology prior to Thun worked closely with me on the
overall CA CPS I follow-up study from 1991 until 2001
because he felt that this was a valuable project. He was a
co-author on the first version of the ETS and mortality
paper when it was submitted to the New England Journal of
Medicine in 2001 and was co-author on my first publica-
tion based on the CA CPS I cohort, which dealt with
smoking cessation and mortality trends [31]. He was not
able to remain as co-author on the ETS and mortality
paper after 2001 because of his retirement from the ACS
and his growing distance from the project.
3) It is absolutely false that "this study is neither reliable
nor independent." First, this study is just as reliable as
other epidemiological studies that have been conducted
in a similar manner Indeed, the BMJ peer review process
found that the results of the study were sound and suffi-
ciently reliable to be worthy of publication and the ACS
has thus far identified no specific errors in the study. Sec-
ond, the study was conducted independent of influence
from both the ACS and the tobacco industry.
4) It is absolutely false that "The study suffers from a crit-
ical design flaw: the inability to distinguish people who
were exposed to secondhand smoke from those who were
not." This cohort study was done in the same way as theEpidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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other spousal smoking studies and our 1999 follow-up
questionnaire survey results clearly showed that there
were subjects who had varying degrees of exposure to ETS
as shown in Tables 1 and 2 of the BMJ paper. This issue
was clearly addressed in the BMJ paper in response to
Thun's 1999 concerns about this issue [32].
5) It is absolutely false that "exposure to secondhand
smoke was so pervasive [in 1959] that virtually everyone
was exposed to ETS, whether or not they were married to
a smoker." The results of the 1999 survey shown in Table
4 of the BMJ  paper clearly showed that among never
smokers married to never smokers as of 1959, 43.5% of
males and 61.7% of females reported no regular exposure
to cigarette smoke from others in work or daily life as of
1999.
Although the ACS disputes the validity of my 1999 survey,
they have not conducted their own ETS exposure survey of
the approximately 50 million Americans who were born
before 1950 and who are currently alive. Such a survey
would yield actual evidence as to whether or not all Amer-
icans alive during the 1950s and 1960s were equally
exposed to ETS. The ACS cannot simply make an unsub-
stantiated claim that "virtually everyone was exposed to
ETS" and expect this claim to negate all the evidence pre-
sented in my BMJ paper.
In addition to the published letters cited above, we sub-
mitted to the BMJ  on June 30, 2003 Manuscript BMJ/
2003/084269, a detailed commentary that vigorously
defended specific aspects of our BMJ paper. We showed
that there was, in fact, substantial agreement between our
results regarding ETS and those of the ACS and pointed
out inconsistencies in ACS findings that had not been pre-
viously noted. Unfortunately, on September 19, 2003 the
BMJ declined to publish this commentary, which would
have helped resolve the controversy that had erupted over
our BMJ paper. We then spent over two years attempting
to publish various portions of this commentary in other
journals until we successfully published in 2006, as
described in our January 24, 2006 rr to bmj.com [33]. Por-
tions of Manuscript BMJ/2003/084269 are presented later
in this paper and the entire manuscript is posted for his-
torical reference [34].
In spite of the numerous attacks described above, the BMJ
has stood behind the BMJ paper since its publication. For
all of the vehemence of the rrs, only about 3% referred to
actual data in the paper and none identified anything
approaching scientific error or scientific fraud [16].
Indeed, our paper was ranked among the "Top tens from
bmj.com" in 2003 [3531]. BMJ  Editor Richard Smith
strongly defended his decision to publish the paper on
both May 18, 2003 [36] and August 30, 2003 [37]. Fur-
thermore, Smith again defended this decision in his 2006
book, The Trouble with Medical Journals, in which he stated
"it would be antiscience to suppress systematically one
source of research" [38]. To date, no impropriety, bias, or
omission has been identified in the review process and no
error in the results has been identified in the paper, not
even by Thun, who is in a position to check our findings
and to publish additional findings.
Support for the BMJ paper from Other Epidemiologic 
Research
To further document the validity of our BMJ  findings,
Kabat and I compared them with the other U.S. epidemi-
ologic evidence on ETS and coronary heart disease
(CHD), in our 2006 peer-reviewed meta-analysis of envi-
ronmental tobacco smoke and CHD mortality in the
United States [39]. This comprehensive meta-analysis
focuses on the U.S. cohort studies of ETS and CHD death
in never smokers. These cohort studies are all fairly similar
in design; ETS exposure was approximated by spousal
smoking; CHD death was the endpoint; and they consti-
tute virtually all the U.S. evidence and the majority of the
world-wide evidence. In contrast to the previous major
meta-analyses on this topic, such as the one in 1999 by
Thun [32], our analysis includes the results of our 2003
study and the 1995 study by LeVois and Layard based on
CPS I data [40]. We have applied consistent criteria to the
selection of results included in the analysis. The results are
summarized in terms of overall relative risks and dose-
response relationships. In addition, available data on mis-
classification of ETS exposure, personal monitoring of
actual ETS exposure, and dose-response data for active
smoking are discussed in order to characterize the esti-
mates of ETS exposure in epidemiologic studies.
Contrary to the claims of the ACS and other critics, our
results do not differ in any material way from those of the
other studies, particularly for females. A further example
of the ACS misrepresentations on the ETS issue can be
found in the following simple comparison of statements
about the findings in their major 1982 Cancer Prevention
Study (CPS II) cohort. In the May 15, 2003 ACS press
release Harmon J. Eyre, MD, stated: "CPS-II is one of more
than 50 studies now published that have shown non-
smokers married to smokers have an increased risk of lung
cancer" [8,9]. But, the 1995 doctoral dissertation based on
CPS II by Victor Cardenas, "Environmental tobacco smoke
and lung cancer mortality in the American Cancer Society's
Cancer Prevention Study II", was inconclusive [41]. The dis-
sertation abstract states: "This study found no evidence of
an association between self-reported ETS and lung cancer
risk among nonsmokers. However, using spousal smok-
ing habits to assess exposure, we found ETS is only
weakly, and not statistically significantly, related to lung
cancer risk among nonsmoking women in seven years ofEpidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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follow-up of the CPS II cohort." [41]. Even though our
findings are entirely consistent with Cardenas' findings,
Eyre impugned our study with his statement: "Bad science
can haunt us for generations. And regrettably, if question-
able studies make it to publication, the damage is done."
[8,9].
Furthermore, we specifically refuted the unsubstantiated
claim by Thun that our BMJ  study is "fatally flawed
because of misclassification of exposure" [42]. Thun
implied that virtually everyone in the U.S. during the
1950s and 1960s was equally exposed to ETS because it
was so pervasive. Results from four independent surveys,
as well as our 1999 CA CPS I survey, show that Americans
were not equally exposed to ETS. Additional surveys show
that exposure to ETS comes primarily from spousal smok-
ing, not public smoking, particularly for females. Indeed,
there was a clear relationship between spousal smoking
and self-reported ETS exposure among never smokers
who lived a major portion of their life before the introduc-
tion of restrictions on public smoking in the 1970s. One
of these surveys is contained in the 1995 Cardenas disser-
tation [41]. Although Thun served on the Cardenas disser-
tation committee, to my knowledge, he has never cited
results from this dissertation.
We found that when all relevant studies are included in
the meta-analysis and the results of the individual studies
are appropriately combined, current or ever exposure to
ETS, as approximated by spousal smoking, is associated
with roughly a 5% increased risk of death from CHD in
never smokers, not the widely cited 25% in the meta-anal-
yses of Thun and others. Furthermore, we found no dose-
response relationship and no elevated risk associated with
the highest level of ETS exposure in males or females.
Another paper which sheds light on the CPS II findings
concerning ETS is a 1995 analysis which linked data on
ambient air pollution from 151 U.S. metropolitan areas
with mortality data from CPS II individuals who resided
in those areas [43]. The results of this analysis showed that
in never smokers there was a statistically significant asso-
ciation of all cause mortality with both sulfate and fine
particle concentrations after controlling for covariates,
including "hours per day of ETS exposure." The authors, one
of whom was Thun, did not report the specific results for
the confounding variable of ETS exposure. However, in
order to resolve a major dispute over the validity of the
results in this air pollution analysis [44], a reanalysis was
conducted in 2000 by the Health Effects Institute (HEI)
[45]. The Cox proportional hazards regression model
(PHREG) results included in Appendix F of the resulting
HEI Reanalysis Report make it clear that the independent
variable "passive" (hours per day of ETS exposure) shows
no association with mortality from lung cancer, cardiop-
ulmonary disease, or all causes in never smokers [46].
Results are shown as a relative risk (RR) and 95% confi-
dence interval (CI). For lung cancer in CPS II, RR(passive)
= 1.020 (0.938–1.110) for males, 1.004 (0.995–1.013)
for females, and 1.005 (0.957–1.055) for both sexes.
These relative risks agree well with those in my CA CPS I
study, where RR(7 level index) = 0.88 (0.70–1.10) in
males and RR(8 level index) = 0.97 (0.90–1.05) in
females. For cardiopulmonary diseases in CPS II, RR(pas-
sive) = 1.004 (0.987–1.021) for males, 1.015 (1.000–
1.029) for females, and 1.010 (0.999–1.021) for both
sexes. For all causes in CPS II, RR(passive) = 0.996
(0.984–1.009) for males, 1.004 (0.995–1.013) for
females, and 1.001 (0.994–1.009) for both sexes. A key
portion of the actual PHREG computer printout for these
diseases for males, females, and both sexes has been
assembled and posted [46]. The PHREG program used in
the CPS II study [43,46] is the same as that used in the CA
CPS I study [1].
My BMJ results for coronary heart disease are also consist-
ent with those in the Western New York State study pub-
lished in the October 9, 2006 Archives of Internal Medicine,
which found "After adjustment for covariates, exposure to
secondhand smoke [SHS] was not significantly associated
with an increased risk of myocardial infarction [MI]" [47].
Furthermore, this study concluded "Exposure to SHS has
declined sharply among nonsmokers in recent years. In
the absence of high levels of recent exposure to SHS,
cumulative lifetime exposure to SHS may not be as impor-
tant a risk factor for MI as previously thought." This study
was entirely independent of my study and was done with-
out tobacco industry funding and came to the same con-
clusion with regard to heart disease. Finally, my BMJ
results for lung cancer in the CA CPS I cohort are consist-
ent with those of the original 1981 ACS analysis of the
nationwide CPS I cohort [48]. This analysis examined
lung cancer mortality during 1960–1972 and found
"Compared with nonsmoking women married to non-
smoking husbands, nonsmokers married to smoking hus-
bands showed very little, if any, increased risk of lung
cancer." This analysis was entirely funded by and con-
ducted by ACS and came to the same conclusion as my
BMJ analysis.
Ongoing Misrepresentations Regarding ETS
Much of the evidence above is not being properly pre-
sented and there is misrepresentation of other evidence.
For instance, serious misrepresentation of CPS II results is
evident when one examines the 1997 Cardenas peer-
reviewed paper [49], which was based on the 1995 Carde-
nas dissertation [41]. Table 4 of the Cardenas paper
presents exposure to spousal smoking among women by
the husband's level of smoking, but is deceptively labeled.
Women with the highest level of exposure, labeled "40+Epidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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cpd by spouse", have a RR of 1.9 (95% CI 1.0–3.6) and
the P for dose-response trend is 0.03 (cpd = cigarettes per
day). However, Table 38 of the Cardenas dissertation
makes clear that the RR for spouses of current smokers of
40+ cpd is only 0.9 (95% CI 0.2–3.9) and the P for trend
is 0.34. If it were not for Table 38 the reader would not
know that Table 4 is based on the combination of current
and former smokers. This combination of current and
former smokers by cpd is highly unorthodox, has not
been done in other ETS studies, and is not meaningful for
assessing a trend based on current spousal smoking. The
Cardenas dissertation makes it very clear that there is no
dose-response relationship between spousal smoking and
lung cancer in CPS II. Key sections of Cardenas' Tables 4
and 38 are shown side by side in Table 1 and they reveal
a serious discrepancy in the presentation of the same data.
Because Cardenas' Table 38 appears to present the under-
lying findings and because these findings contradict Eyre's
statement above, the ACS should clarify this major dis-
crepancy. However, no clarification has been made and
only the positive dose-response relationship in Cardenas'
Table 4 is ever cited [49].
For instance, Cardenas' Table 4 findings are now cited in
the 2004 WHO IARC Monograph 83 "Tobacco Smoke
and Involuntary Smoking" [50]. This major 1452-page
report contains a review of the epidemiologic evidence on
ETS and lung cancer on pages 1231–1271 [51]. The sec-
tion "Exposure-response relationships" on page 1236
contains the statement "The study by Cardenas et al.
(1997) also found a significant exposure-response rela-
tionship. When the husbands smoked 1–19, 20–39, ≥40
cigarettes/day, the relative risks for women exposed to sec-
ondhand smoke were 1.1, 1.2, and 1.9 respectively (p
value for trend test, 0.03)".
In addition, a January 2004 J Natl Cancer Inst (JNCI)sum-
mary of IARC Monograph 83 shows results for ≥40 ciga-
rettes/day in Table 3 and it contains the erroneous value
RR = 1.9 [52]. Obviously Thun, a member of the IARC
Working Group for Monograph 83, did not notify the
IARC Working Group about the 1995 Cardenas disserta-
tion. This type of selective analysis and presentation of
results has been termed "publication bias in situ" and it is
often difficult to detect [53]. I was able to detect this irreg-
ularity only because I knew of the Cardenas dissertation.
In other scientific fields, the type of data manipulation
done in Cardenas' Table 4 would most likely be treated as
a serious ethical violation. Also, it is noteworthy that 14
authors of the JNCI article signed an August 30, 2003 BMJ
letter criticizing my BMJ paper, but then made no men-
tion of my paper in their January 2004 JNCI article.
Continuing ACS Campaign to Discredit the BMJ Study
Although I have refuted the erroneous statements in their
May 15, 2003 press release, the ACS has shown no interest
in correcting the record with regard to me and my
research. Their press release has been posted on up to
1,000 locations on the Internet during the past four years,
based on Google searches of the phrase "American Cancer
Society Condemns Tobacco Industry Study." It is still
posted on many websites in addition to ACS's own web-
site. Our BMJ and Lancet letters and our new meta-analysis
defending the validity of our BMJ paper are being ignored
by the ACS. Instead, the ACS and other activist organiza-
tions continue to post defamatory information about us
and our research.
Our new meta-analysis shows that the relationship
between ETS and CHD in U.S. never smokers is very weak
(estimated relative risk of 1.05 with no dose-response
relationship) [39]. Yet the ACS continues to state in their
2007 "Cancer Facts and Figures" that "ETS causes an esti-
mated 35,000 deaths from heart disease in persons who
are not current smokers" (page 36) [54]. The source the
ACS uses for this CHD death estimate is a 1992 JAMA
paper [55], even though more than 90% of the U.S. epide-
miologic evidence has been published since 1992. Our
new meta-analysis shows that the vast majority of the
existing U.S. evidence originates from the ACS CPS I and
CPS II cohorts, yet the ACS simply ignores or dismisses
most of this evidence. The CPS I and CPS II evidence is
summarized in Table 2, which is taken from Table 6 of our
meta-analysis paper [39].
Continuing Glantz Campaign to Discredit Enstrom
Beginning with his activities at the time of the publication
of our BMJ paper, Glantz has continually attacked me and
my research, in spite of the fact that we are both estab-
lished, long-term faculty members in the University of
California system. Glantz is well-known as a long-time
anti-smoking activist [10,56], whose ultimate goal is
achieving a society free of smokers [57]. However, as a UC
faculty member, he is supposed to adhere to the UCSF
Campus Code of Conduct [58] and the UC Standards of
Ethical Conduct [59]. For instance, the Code of Conduct
states "Misconduct or Misconduct in Science means fabri-
cation, falsification, plagiarism, or other practices that
seriously deviate from those that are commonly accepted
within the scientific community for proposing, conduct-
ing, or reporting research." The UC Standards of Ethical
Conduct states "Members of the University community
are expected to conduct themselves ethically, honestly,
and with integrity in all dealings."
However, based on his clearly documented written and
verbal attack on me, he has not adhered to these codes.
Indeed, I have spent the past four years responding to hisE
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) Table 1: Comparison of the CPS II dose-response results of 1995 Cardenas disseration and 1997 Cardenas paper: relative risk (RR & 95% CI) of lung cancer death by ETS exposure 
(spousal smoking) among female never smokers in CPS II. Definition in 1995 Cardenas dissertation [41]: 'Analyses restricted to nonsmoking spouses married to nonsmoking spouses 
and those married to cigarette smokers (and not other type of tobacco), with complete smoking data, married once at a time of interview, and with valid data on age at first 
marriage.' Definition in1997 Cardenas paper [49]: 'The referent group includes never-smoking women married to husbands who did not smoke during the marriage. The exposed 
categories are split into approximate tertiles, and are restricted to never-smokers married to cigarette smokers with complete smoking data, married once, and with valid 
information on age at marriage.'
1995 Cardenas dissertation [41] 1997 Cardenas paper [49]
Spousal smoking (cigarettes per day) Deaths/Person-years 1982–89 CPS II 
Fully-adjusted RR (95% CI)
Deaths/Person-years 1982–89 CPS II 
Fully-adjusted RR (95% CI)
Cigarettes per day by spouse Deaths/Person-years 1982–89 CPS II 
Fully-adjusted RR (95% CI)
Table 38 as shown on page 117 Proper summary of Table 38 data Table 4: improper summary of Table 38 data
Never 30/311,333 1.0 30/311,333 1.0 0 (never) 30/333,946 1.0
Former(1–19) 4/61,677 0.6 (0.2–1.8)
Former(20–39) 12/120,585 0.8 (0.4–1.7)
Former(40+) 11/49,304 2.0 (1.0–4.0)
Former – total 27/231,566 1.13 (0.72–1.78)
Current(1–19) 5/32,524 1.7 (0.7–4.4) 5/32,524 1.7 (0.7–4.4) 1–19 (current or former) 9/83,074* 1.1 (0.5–2.2)
Current(20–39) 10/69,060 1.6 (0.8–3.4) 10/69,060 1.6 (0.8–3.4) 20–39 (current or former) 22/179,751* 1.2 (0.7–2.2)
Current(40+) 2/24,900 0.9 (0.2–3.9) 2/24,900 0.9 (0.2–3.9) 40+ (current or former) 13/71,618* 1.9 (1.0–3.6)
P test for trend for 'former' P = 0.29
P test for trend for 'current' P = 0.34 P test for 'current or former' P = 0.03
* Current and Former CombinedE
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Table 2: Dose-response relationship between ETS exposure and CHD mortality. Relative risk of spousal smoking related to CHD deaths among never smokers in CA CPS I [1], CPS II 
[82], and CPS I [40] and in the summary RR of the three studies.
Spousal smoking 1960–98 CA CPS I 
Age-adjusted RR (95% CI)
1982–89 CPS II 
Fully-adjusted RR (95% CI)
1960–72 CPS I 
Age-adjusted RR (95% CI)
Summmary'Age-adjusted' RR (95% CI)
Enstrom [1] (extracted from Tables 7 & 8) Steenland [82](extracted from Table 2) LeVois [40] (extracted from Table 4) Enstrom + Steenland + LeVois
Males
Never 1.00 1.00 1.00 1.00
Former 0.94 (0.78–1.12) 0.96 (0.83–1.11) 0.95 (0.83–1.09) 0.95 (0.87–1.04)
current
1–19 cigs/day 0.91* (0.78–1.06) 1.33 (1.09–1.61) 0.99 (0.89–1.09) 1.02 (0.94–1.10)
20 cigs/day 0.92 (0.74–1.15) 1.17 (0.92–1.48)
20+ cigs/day 0.96* (0.83–1.11) 1.02 (0.92–1.12)
21+ cigs/day 1.20* (0.88–1.64) 1.09 (0.77–1.53)
Females
Never 1.00 1.00 1.00 1.00
Former 1.02 (0.93–1.11) 1.00 (0.88–1.13) 0.99 (0.93–1.05) 1.00 (0.95–1.05)
Current
1–19 cigs/day 1.07* (0.96–1.19) 1.15 (0.90–1.48) 1.04 (0.97–1.12) 1.05 (0.99–1.12)
20 cigs/day 1.04 (0.92–1.16) 1.07 (0.83–1.40)
20–39 cigs/day 1.06 (0.98–1.15) 1.04 (0.98–1.10)
21–39 cigs/day 0.95 (0.80–1.12) 0.99 (0.67–1.47)
40+ cigs/day 0.83 (0.65–1.06) 1.04 (0.67–1.61) 0.95 (0.78–1.15) 0.92 (0.79–1.06)
* indicates RR was based on combining other RRsEpidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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false and misleading statements and defending my hon-
esty and scientific integrity. The full details of his cam-
paign are too extensive to present here, but the selected
examples below demonstrate the tactics that he used
against me and the epidemiologic research that I have
been conducting at UCLA.
On July 25, 2003 Neal L. Benowitz, MD, UCSF Professor
of Medicine, and Glantz co-wrote an eight-page letter to
the UC Vice Provost for Research Lawrence Coleman
which attempts to make the case that acceptance of
tobacco industry funding for research violates current
Regents and University policy and should be ended [60].
On pages 3 and 4 of this letter they claim: "The most
recent example of how the tobacco industry uses funding
of university research as part of its for propaganda cam-
paign is a May 17, 2003 study from UCLA on the health
effects of secondhand smoke published in the British Med-
ical Journal. . . . There is little possibility that it will be
taken seriously in scientific circles. . . . this paper would go
down as one bit of poor research done at a university with
a reputation for high quality scholarship that slipped into
a good journal because of the foibles of the peer review
process."
On March 8, 2005 Glantz participated with other UC fac-
ulty members in a San Francisco based KQED radio pro-
gram entitled "Funders and Academic Research: Forum
assesses the controversy surrounding the relationship
between funders and academic research," which can be
listened to on the Internet and audio files [61]. During
this program Glantz attempted to discredit well qualified
scientists and their peer-reviewed research publications by
inappropriately linking them to the tobacco industry. The
"scandal" about me and my BMJ study was discussed dur-
ing minutes 17–19 of this 52 minute program, when
Glantz made several clearly false and inflammatory state-
ments. First, Glantz claimed that the BMJ study "was not
funded by the American Cancer Society," but was "done
with Philip Morris' money." Actually, the study was
funded by ACS from 1959 to 1990, by the UC Tobacco-
Related Disease Research Program from 1991 to 1997,
and by the Center for Indoor Air Research (CIAR) from
1998 to 2003. Philip Morris provided no direct funding
for this study and had no role in its conduct. Then, Glantz
stated that I was "a damn fool" who was told by ACS that
I "made inappropriate use of the data", an unsubstanti-
ated claim made only after Glantz and ACS learned of my
results. Then, Glantz implied that I was "advocating a pro-
tobacco position" when I have never done so. Finally,
Glantz claimed "the science that the UCLA study did was
crap", whereas it clearly conformed to the standards of
epidemiologic research. These statements indicate the
unprofessional approach used by Glantz to attack scien-
tific findings with which he disagrees and to advocate
positions that are not supported by the facts.
Glantz's arguments for banning tobacco industry funding
of research at UC have been rejected in favor of academic
freedom. The UC administration has expressed its strong
support for academic freedom and UC Vice Provost for
Research Coleman has stated "Academic freedom must be
absolute or no one has it" [62]. On May 11, 2005 the UC
Academic Senate adopted a strong Academic Senate Reso-
lution on Research Funding Sources which clearly sup-
ports the right of individual UC faculty members to accept
research support from any source, including the tobacco
industry, as long as this funding adheres to University pol-
icy [63]. In spite of this strong faculty resolution, in Sep-
tember 2006 Glantz brought the issue of a ban on tobacco
industry funding to the UC Regents, the governing body
of the University [64]. Glantz cited my BMJ study as one
rationale for such a ban in written documents [65] and in
a January 18, 2007 presentation before the UC Regents
[66]. The UC Regents requested advice on this issue from
the UC Academic Senate, which spent several months
carefully evaluating the matter [67]. My perspective,
including a defense of my research, my funding, and my
scientific integrity, was presented to the UC Academic
Senate in April 2007 [68]. In May 2007 representatives of
the UC Academic Senate voted almost unanimously (15
to 1 by the Academic Council and 44 to 5 by the Academic
Assembly) in favor in academic freedom and against a
proposed ban on tobacco industry funding advocated by
Glantz [69-71].
One final example of Glantz's unprofessional treatment
of my research is contained in his May 24, 2005 Circula-
tion report, where he attempts to make the case that pas-
sive smoking has nearly the same impact as active
smoking on cardiovascular effects [72]. In his meta-analy-
sis of the relation between ETS and CHD, he found "The
pooled relative risk computed with a random-effects
model (computed with Stata Version 7) was 1.31 (95%
CI, 1.21 to 1.41), similar to the estimates of earlier meta-
analyses." To achieve this result, he omitted the two larg-
est studies, which represent a major portion of the availa-
ble evidence. My BMJ study, which began in 1960 [1], was
omitted based on his unsubstantiated claim that it had
"serious misclassification bias" and the 1995 study by
LeVois and Layard, which also began in 1960 [40], was
omitted without comment and was not even cited. How-
ever, Glantz included the other cohort studies which
began in the 1960s and 1970s without any comment
about their misclassification bias. Kabat and I fully
addressed all these studies and the issue of misclassifica-
tion bias in our 2006 meta-analysis [39]. Glantz's biased
analysis regarding the relation between ETS and CHD isEpidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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evident when his 2-page 2005 meta-analysis [72] is com-
pared with our 12-page 2006 meta-analysis [39].
Jonathan M. Samet, M.D., and the 2006 Surgeon General's 
Report
False and misleading statements about my research were
also made by Jonathan M. Samet, M.D, M.S., who has
played a prominent role in reviews of the epidemiologic
evidence on ETS for over 20 years. First, Samet made a
statement that neither he nor anyone else has substanti-
ated in the May 16, 2003 Los Angeles Times, when he
described my BMJ paper as "one very flawed study" that
"just doesn't contribute" [22]. Then, he co-signed serious
accusations about my research that appeared in a May 30,
2003 BMJ rapid response [20] and an August 30, 2003
BMJ  letter [73]. These two items stated "Enstrom and
Kabat's conclusions are not supported by the weak evi-
dence that they offer, and although the accompanying
editorial alluded to 'debate' and 'controversy', we judge
the issue to be resolved scientifically, even though the
'debate' is cynically continued by the tobacco industry."
To understand the outlandish nature of these accusations,
recall that we used a large and highly respected dataset
and accepted epidemiologic methods; we reported study
details in the paper itself, in the "Prepublication History",
and in our subsequent letters; we have supported our con-
clusions to a greater extent than can be found for any
other study of ETS and mortality; our methods have never
been substantively challenged; and our results are consist-
ent with the entire body of U.S. evidence [39].
These statements from Samet might have been somewhat
plausible if he had any evidence that there were errors in
my 2003 paper or that I was "pro-tobacco" based on my
research before 2003. But neither he nor other critics have
made a plausible case for fundamental errors in my paper,
and I have never been "pro-tobacco." Samet has been
aware of my epidemiologic research since we both partic-
ipated in the August 23–25, 1978 National Cancer Insti-
tute Workshop on "Populations at Low Risk of Cancer"
held in Snowbird, Utah. The proceedings of the work-
shop, including the list of participants, were published in
JNCI in November 1980 [74]. I gave three talks at this
Workshop and two of them described the reduced cancer
death rates among nonsmokers, one dealing with Mor-
mons [75] and another dealing with a representative sam-
ple of U.S. nonsmokers [76]. Indeed, I have investigated
the healthy lifestyles of Mormons and other nonsmokers
during my entire epidemiologic career [77,78].
Further evidence of Samet's willingness to dismiss scien-
tific evidence when it does not support his agenda appears
in the June 27, 2006 release and publication of the 727-
page Surgeon General's Report on "The Health Conse-
quences of Involuntary Exposure to Tobacco Smoke" [79].
Samet was the Senior Scientific Editor of this report and
the most influential epidemiologist involved with the
report [80]. In addition, Glantz was a Contributing Editor
and Thun was a Reviewer on this report. Although Samet,
Thun, and Glantz were fully aware of the importance of
my BMJ paper, as evidenced by their extensive efforts to
discredit it, the paper was simply omitted from the Sur-
geon General's Report without comment. A search for
"enstrom j" of the entire PDF version of the report [79],
reveals that the only mention of the BMJ paper is in the
Appendix on page 673, where it is listed as one of the
papers not included in the report. Another search reveals
that the BMJ paper was omitted without explanation from
the database for the Report [81]. This database was pre-
pared by Johns Hopkins University and the Centers for
Disease Control and Prevention's Office on Smoking and
Health. It includes "approximately 900 key articles regard-
ing involuntary smoking and disease outcomes" and sup-
posedly "reflects the most recent findings in the scientific
literature."
In order to illustrate the selective and unscientific nature
of this omission, I examined the references used in Chap-
ters 1–10 of the Surgeon General's Report and the refer-
ences in the Appendix that were not used. Of 38 total
references from 2003, 33 were used in Chapters 1–10 and
only 5 references, including the BMJ paper, were not used.
Of 71 references from 2004, 53 were used and 18 were not
used; of 39 references from 2005, 26 were used and 13
were not used; of 22 references from 2006, 7 were used
and 15 were not used. In summary, the report used 119
references from 2003–2006, but omitted without com-
ment the 2003 BMJ paper. The BMJ paper was the only
U.S. study relating ETS to lung cancer and coronary heart
disease that was omitted. Because of this omission, the
Surgeon General's Report does not accurately reflect all
the peer-reviewed epidemiologic evidence on the relation
of ETS to lung cancer and coronary heart disease mortality
in the U.S.
Chapter 7, page 423, reports: "This chapter considers the
full body of evidence on secondhand smoke exposure and
lung cancer published through 2002, the ending date for
the systematic review of the epidemiologic studies." Based
on comparing never smokers ever married to a smoker
with never smokers never married to a smoker, a world
wide relative risk (RR) of 1.21 (1.13–1.30) was reported
on page 435. However, there is no reason for an ending
date of 2002, given that other sections of the report cite
results published during 2003–2006 (by my count 119
such publications are cited). It appears that the ending
date of 2002 was intentionally selected in order to exclude
my 2003 BMJ results. Consequently, the above worldwide
RR is misleading because it does not reflect that fact that
my results substantially weaken the U.S. evidence [1,29].Epidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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My own meta-analysis of all U.S. spousal smoking studies,
yields a U.S. RR of 1.10 (1.00–1.21), which barely consti-
tutes a relationship.
Chapter 7 contains this inaccurate statement on page 435:
"There were no significant differences in the RR estimates
by geographic area; the point estimate was 1.15 (95 per-
cent CI, 1.04–1.26) for studies conducted in the United
States and Canada, 1.16 (95 percent CI, 1.03–1.30) for
studies conducted in Europe, and 1.43 (95 percent CI,
1.24–1.66) for studies conducted in Asia." Obviously, the
RR = 1.43 for studies in Asia is statistically greater than the
RR = 1.15 for studies in U.S. and Canada and the RR =
1.16 for studies in Europe. Indeed, there is substantial var-
iation around the world and all these results cannot be
accurately represented by a single RR of 1.21. This geo-
graphic variation should have been properly acknowl-
edged in the Report.
Chapter 8 contains on page 521 selective criticism about
and dismissal of the analysis by LeVois and Layard of ETS
and CHD deaths in the ACS CPS I and CPS II studies [40].
This paper is important because of its size and statistical
power, as discussed in our 2006 meta-analysis of ETS and
CHD deaths in the U.S. [39]. One basis for the dismissal
is the inaccurate statement, "The investigators did not dis-
tinguish between current exposures from spousal second-
hand smoke and former exposures, nor did they
separately report the effect of current spousal smoking on
the risk of CHD." Table 4 of the LeVois and Layard paper
clearly shows results for three levels of current ETS expo-
sure for both males and females. Furthermore, Table 2
summarizes the dose-response relationship between ETS
and CHD deaths based on the results from the three larg-
est U.S. studies [1,40,82]. There is no meaningful differ-
ence in the results for these studies and no dose-response
relationship in any of them.
Furthermore, note that the meta-analysis of ETS and CHD
is summarized in Figure 8.1 on page 524. Since this figure
only shows studies through 2001 it obviously omits the
2003 BMJ study.
The BMJ study has a major impact on the meta-analysis,
as pointed out in our 2003 BMJ letter [29] and our 2006
meta-analysis [39]. Note that inclusion of BMJ  results
yields a relative risk (RR) of CHD death in the U.S. of 1.05
(0.99–1.11), based on a comparison of current to never
exposure to ETS. This is much less than the summary RR
(exposed/unexposed) of 1.27 (1.19–1.36) contained in
Figure 8.1. The Surgeon General's Report should have
pointed out that the ETS and CHD relationship is much
larger outside of the U.S. than it is within the U.S. We esti-
mated that the RR outside the U.S. is approximately 1.5
[39] and the 1999 Thun meta-analysis found the RR was
1.41 (1.21–1.65) [32]. This large difference between the
RRs within the U.S. and those outside of the U.S. is worthy
of further discussion and investigation, in order to deter-
mine if it is a real difference or an anomaly due to meth-
odological issues.
The Introduction of the Surgeon General's Report makes
the statement that "about 50,000 excess deaths result
annually from exposure to secondhand smoke (Cal/EPA
2005). Estimated annual excess deaths for the total U.S.
population are about 3,400 (a range of 3,423 to 8,866)
from lung cancer, 46,000 (a range of 22,700 to 69,600)
from cardiac-related illnesses, and 430 from SIDS." [79].
Given the fact that the two largest epidemiologic studies
on ETS and tobacco-related mortality [1,40] have been
omitted from the Surgeon General's Report and the fact
that these two U.S. studies suggest a substantially weaker
ETS and mortality relationship in the US, the above esti-
mate of excess deaths appears to be an intentional exag-
geration of what the entire body of scientific evidence
shows. A complete evaluation of all the peer-reviewed
U.S. epidemiologic evidence suggests that ETS exposure is
associated with a much smaller number of lung cancer
and CHD deaths in U.S. never smokers. Furthermore,
there is not a "causal" relationship by traditional epidemi-
ologic standards.
An August 23, 2006 "research news and perspective"
report in JAMA questioned various aspects of the Surgeon
General's Report, particularly findings regarding the acute
effects of small amounts of ETS exposure and the claim by
the Surgeon General that "There is no safe level of expo-
sure to secondhand smoke" [83]. This JAMA report is par-
ticularly noteworthy because it quotes two experts who
have extensive experience regarding the ETS issue. Michael
Siegel, MD, MPH, a professor of social and behavioral sci-
ences at Boston University School of Public Health and a
prominent tobacco control researcher, told JAMA "We're
really risking our credibility [as public health profession-
als or officials] by putting out rather absurd claims that
you can be exposed briefly to secondhand smoke and you
are going to come down with heart disease or cancer. Peo-
ple are going to look at that and say that's ridiculous."
Siegel's own paper expanding on this point is published
alongside the present article [84]. Furthermore, since
March 2005, Siegel has posted many detailed and insight-
ful analyses regarding ETS and tobacco control on his per-
sonal website, "The Rest of the Story: Tobacco News
Analysis and Commentary" [85]. Each post includes
"Comments" from readers who provide additional
insights. For instance, on June 28, 2006, he posted "Sur-
geon General's Communications Misrepresent Findings
of Report; Tobacco Control Practitioners Appear Unable
to Accurately Portray the Science" [86].Epidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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John C. Bailar III, MD, PhD, a prominent epidemiologist
and biostatistician, who is Professor Emeritus at the Uni-
versity of Chicago, told JAMA "It doesn't make sense for
the cardiovascular risk of secondhand smoke to be as high
as one third of the risk from direct smoking. . . . That's a
far bigger ratio than risk for lung cancer and it's hard for
me to believe that it's real" [83]. These comments are sim-
ilar to those in his March 25, 1999 NEJM editorial on ETS
and coronary heart disease, in which he stated "I regret-
fully conclude that we still do not know, with accuracy,
how much or even whether exposure to environmental
tobacco smoke increases the risk of coronary heart dis-
ease" [87]. On June 7, 2006, just 20 days before the release
of the Surgeon General's Report, the Select Committee on
Economic Affairs of the House of Lords in London issued
an important report on the management of risk, which
suggests that passive smoking in England may be a rela-
tively minor health risk [88]. The committee obtained tes-
timony from Professor Sir Richard Peto of the University
of Oxford on February 14, 2006 [89]. Sir Richard's testi-
mony clearly states the substantial doubt that he has
about the quantitative health risks of passive smoking
[90,91]. The very fact that two major reports published in
the same month, June 2006, come to substantially differ-
ent conclusions about the health risks of ETS indicates
that these risks are still uncertain and difficult to measure
accurately.
Further evidence of the uncertainty regarding the health
risks of ETS is contained in the June 28, 2007 Nature news
article on ETS. Various claims made by Glantz about the
acute and chronic health effects of ETS are questioned by
Peto, Bailar, and Siegel, who restated their concerns that
the dangers of ETS have been exaggerated [92]. For
instance, Peto stated "Passive smoking must kill some
people, but the big question is how many." This statement
clearly underscores the existing uncertainty and directly
contradicts the June 27, 2006 statement by U.S. Surgeon
General Richard H. Carmona that "The debate is over"
regarding the health effects of secondhand smoke [93].
Jonathan M. Samet, M.D., and United States of America v. 
Philip Morris USA, et al
One particularly pernicious aspect of the attack described
above is the fact that my BMJ paper is now part of the larg-
est ($280 billion) Racketeer Influenced and Corrupt
Organizations Act (RICO) lawsuit ever filed, United States
of America v. Philip Morris USA, et al. [Civil Action No.
99-CV-02496(GK)] [94,95]. My research and I are
described in a defamatory way on pages 821–830 within
the section "Defendants Used Their Jointly Controlled
Organizations to Promote Their Agenda Through Sympo-
sia, Publications and a Roster of Long-time Paid Scien-
tists" of the 2543-page pretrial "UNITED STATES' FINAL
PROPOSED FINDINGS OF FACT (July 2004)" prepared
by the U.S. Department of Justice (USDOJ) [96]. The trial
took place in front of U.S. District Court Judge Gladys Kes-
sler from September 2004 though June 2005 [94]. Addi-
tionally, my research and I are described in a defamatory
way in several places in the 2454-page post-trial docu-
ment "UNITED STATES' FINAL PROPOSED FINDINGS
OF FACT (Incorporating Errata of August 16, 2005)" pre-
pared by the USDOJ [97]. Specifically, my BMJ paper is
listed on page vii of the Table of Contents under the cate-
gory "Cooking the Books: The Manufacture of False Sci-
ence to Support the Industry Position on ETS." On page
493 it is included among "examples of scientific fraud"
and on page 589 it is described as "at best a contamina-
tion of the scientific literature and at worst a scientific
fraud." It is discussed in detail on pages 609–615, where
there are numerous false statements and distortions, such
as, "the Enstrom/Kabat study is yet another self-serving,
unreliable, and scientifically questionable product of the
industry's unabated effort to attack the scientific consen-
sus on passive smoking." Although no actual evidence
was presented of errors in my study or of scientific mis-
conduct on my part, the lawsuit makes it appear that I
have engaged in scientific fraud.
The available evidence indicates that insertion of the BMJ
paper was a collaborative effort of Glantz and Sharon Y.
Eubanks (D.C. Bar No. 420147), Director of the USDOJ
Tobacco Litigation Team from 1999 until December
2005, when she resigned from the USDOJ [98]. The fol-
lowing brief in Civil No. 99-CV-02496 (GK), "REPLY IN
SUPPORT OF THE UNITED STATES' THIRD MOTION TO
COMPEL PRODUCTION OF DOCUMENTS WITHHELD
BY BROWN & WILLIAMSON BASED ON ASSERTIONS
OF PRIVILEGE OR PROTECTION," was prepared by
Eubanks and signed on December 5, 2003. This brief is
posted on the same listserv that Glantz has used to post
other defamatory information about me [99]. Pages 8, 9,
and 14 of this brief contain a misleading and distorted
presentation of my alleged "ties" with the tobacco indus-
try going back "nearly 30 years." This presentation later
appeared in the July 2004 and August 2005 Findings of
Fact of the USDOJ lawsuit. This 2003 brief does not
present any evidence challenging my honesty as a scientist
or the validity of the findings in my BMJ paper. It is simply
an attempt to smear my reputation with inappropriately
constructed "ties" to the tobacco industry, based on the
fact that I had correspondence with the tobacco industry
regarding my epidemiologic research.
On August 17, 2006 District Court Judge Gladys Kessler
issued a 1,653 page Final Opinion concluding that the
tobacco industry had engaged in racketeering [100,101].
Eleven key pages from her decision, including pages dis-
cussing my study, were assembled by Glantz and posted
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section entitled "The 2003 Enstrom/Kabat Study" on
pages 1380–1383, as well as other references to my study.
The Judge repeated in her opinion a number of the mis-
leading and inaccurate statements about my study that are
contained in the 2004 and 2005 Findings of Fact. How-
ever, the Judge identified no specific errors in the study
and identified no scientific misconduct by me. At no time
was I ever given an opportunity to challenge or refute the
statements made about me and my research in the USDOJ
Findings of Fact, in the trial itself, or in the Kessler opin-
ion. I am now in the process of clearing my name in con-
nection with this lawsuit and this paper represents a major
step in that process. Furthermore, on October 31, 2006
the U.S. Court of Appeals of the District of Columbia Cir-
cuit granted the tobacco industry's emergency motion to
stay Judge Kessler's final judgment and remedial order
pending appeal [103]. On May 22, 2007 the U.S. Court of
Appeals issued an order setting the briefing schedule for
the appeal [104].
In formulating her comments about my study, Judge Kes-
sler relied heavily on the testimony of Samet. On page 765
of her decision she states "Dr. Jonathan Samet, a Govern-
ment expert with extraordinary qualifications, is a physi-
cian and epidemiologist with extensive experience
treating patients with lung cancer and COPD." On page
1232 she states: "Dr. Samet is professor and chair of the
Department of Epidemiology at the Johns Hopkins
Bloomberg School of Public Health. He is also a licensed
physician who is board certified in pulmonary and inter-
nal medicine. Dr. Samet is a member of the National
Academy of Sciences' Institute of Medicine, the Board of
Scientific Counselors of the National Cancer Institute, and
EPA's Clean Air Scientific Advisory Committee. He is a
recipient of the Surgeon General's Medallion and has par-
ticipated as an author and/or editor of nine Surgeon Gen-
eral's Reports, including as Consulting Scientific Editor
and author for the 1986 Report. He has participated in
four NCI monographs in its series on smoking and health.
He chaired the 2002 review of active and passive smoking
and health for the International Agency for Research on
Cancer of the World Health Organization. . . . after con-
sidering Dr. Samet's superb academic credentials, his vast
experience working on Surgeon General Reports and NCI
monographs, his continuing practice of medicine, as well
as his demeanor and responsiveness to cross-examina-
tion, the Court fully credits his testimony." On page 1234
she states: "The Court accepts and credits Dr. Samet's con-
clusions, based on his expertise, as well as the other fac-
tual findings herein, that exposure to secondhand smoke
causes lung cancer and coronary heart disease in adults
and a number of respiratory diseases in children."
It is worth repeating the allegations in the Kessler deci-
sion, first to point out that they are the same false and mis-
leading claims about the Enstrom/Kabat study by the
ACS, Samet, Glantz, and others that are described above,
and second to show how obviously incorrect they are. The
Enstrom/Kabat study was not "CIAR-funded and man-
aged" and was not "funded and managed by the tobacco
industry through CIAR and Philip Morris." Although the
study was partially funded by CIAR, it was not managed
by either CIAR or Philip Morris. Indeed, CIAR assigned its
entire award for the study to UCLA in 1999 just before
CIAR was dissolved as a condition of the Master Settle-
ment Agreement [105]. CIAR did not even exist when my
study was being completed. The study was conducted and
published without any influence from the tobacco indus-
try. The claim that the "American Cancer Society had
repeatedly warned Enstrom that using its CPS-I data in the
manner he was using it would lead to unreliable results"
is utterly false and the ACS has produced no documenta-
tion to support this claim. The claim "Enstrom and
Kabat's conclusions are not supported by the weak evi-
dence that they offer" made by Samet and others is utterly
false because our conclusions are fully supported by the
evidence in our BMJ paper, as stated earlier.
In addition, Samet made an inaccurate and incomplete
statement in his Written Direct testimony of September
20, 2004 (page 184, lines 8–9): "When the 2002 meta-
analysis carried out by IARC was redone in 2004 to
include this [Enstrom and Kabat] study, the positive find-
ings were unchanged." [106]. This statement is inaccurate
because the August 30, 2003 BMJ letter signed by Samet
correctly states: "Adding the result from Enstrom and
Kabat to the IARC analysis reduces the pooled estimate to
1.23." [73]. In addition, this statement is incomplete
because Samet failed to state that the Enstrom and Kabat
results reduced the pooled risk ratio estimates for U.S.
studies to about 1.10 for lung cancer and to about 1.05 for
coronary heart disease [39]. The Enstrom/Kabat summary
risk ratios are far below the widely stated summary risk
ratios of about 1.25 and are not consistent with the esti-
mate that "about 50,000 excess deaths results annually
from exposure to secondhand smoke" in the US, as stated
on page 8 of the Surgeon General's Report [79].
Samet made a false statement in this September 20, 2004
testimony when he claimed (page 192, lines 21–23):
"Except for the analyses of CPS I and CPS II presented by
LeVois and Layard in 1995, all other studies have demon-
strated at least a modest increase in risk for fatal and non-
fatal CHD due to secondhand smoke exposure." [106].
Our BMJ study showed no increase in risk for fatal CHD,
other than the insignificant statistical fluctuation that was
also present in the LeVois and Layard paper, and reference
to our study should have been included in Samet's testi-
mony.Epidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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Since no errors had been found in our paper, and since
Kabat and I had clearly declared there was no tobacco
industry influence on our results (and no one has found
any evidence to the contrary), our research did not war-
rant inclusion in the USDOJ lawsuit. The citation of our
study in the Kessler decision appears to be primarily due
to the false and misleading statements about our research
made by Samet. All of this casts doubt on the ability of
Samet to be objective regarding the subject of ETS.
Further evidence of Samet's campaign against me
appeared in the May 4, 2007 Chronicle of Higher Education
as a two-page, 15-inch by 22-inch advertisement "Why do
the University of California Regents still cash checks from
tobacco racketeers?" [107]. This advertisement by "Cam-
paign to Defend Academic Integrity" [108] is an appeal to
UC Regents to implement a tobacco funding ban and it
makes direct reference to me and my tobacco industry
funding. Statements throughout the advertisement falsely
characterize me and my research: "To make vivid how Big
Tobacco co-opted world-class research institutions for its
disinformation and legal defense strategies, the Court
cited the misuse of American Cancer Society data by a
non-faculty researcher at UCLA. . . Big Tobacco's invest-
ment in UCLA bought it the chance to argue falsely, using
UCLA's name, that the science on secondhand smoke was
inconclusive, to battle public health measures. Whatever
the tobacco industry gains from the University, the Uni-
versity loses. The public loses, too." This compounding of
the defamation in the court papers through paid advertis-
ing was signed by 21 prominent individuals who identify
themselves as "among those who support action by the
University of California Regents to refuse all future
tobacco industry funding." The signatories include both
Samet and Eubanks, who obviously have been directly
involved in lobbying the UC Regents, a position that com-
promises their objectivity with regard to my inclusion in
the USDOJ lawsuit. Given the obsessive focus on my
tobacco industry funding, it is noteworthy that there is no
indication of the funding and competing interests of those
associated with this advertisement. The Chronicle of Higher
Education  website states that a "tabloid-page spread"
advertisement like this one costs $22,630 [109], a sum
unlikely to have been paid by the signatories themselves.
Based on the record presented above, Eubanks has obvi-
ously dealt extensively with both Glantz and Samet
regarding the issue of my BMJ paper and the USDOJ law-
suit. She injected herself directly into the UC tobacco
industry funding ban issue with a lecture before the
Regents on July 18, 2007, when she described the USDOJ
lawsuit and its connection to UC [110]. She claimed that
Judge Kessler was "a neutral fact finder, a federal judge,
who made her findings of conspiratorial conduct objec-
tively" based on "a full and fair record." However, she
knows that the record is not objective and that I was never
given any opportunity to defend myself and my BMJ
paper during the trial. In an eloquent defense of academic
freedom at UC, the 2006–2007 UC Academic Senate
Chair John B. Oakley challenged Eubank's linkage of the
USDOJ lawsuit to UC and raised the issue of whether
Judge Kessler's opinion would ultimately be upheld upon
appeal [11188d]. A clearer understanding of this entire
issue can be gained by carefully listening to the Eubanks
and Oakley audio files [110,111].
Jonathan M. Samet, M.D., and Conflict of Interest
Samet has not revealed his competing interests on the
subject of ETS as they relate to the BMJ rr [20], the BMJ let-
ter [73], the IARC Report [50], the JNCI article [52], the
Surgeon General's Report [79], his USDOJ lawsuit testi-
mony [106], or the Chronicle of Higher Education adver-
tisement [107]. Given that Samet has criticized persons
who disagree with his views on ETS because of their com-
peting interests, it is fair and reasonable to ask why he has
failed to report his own substantial competing interests. A
careful examination of the Surgeon General's Report
reveals that it contains no conflict of interest disclosures
for Senior Scientific Editor Samet or for any of the other
editors or reviewers. In addition, an examination of the
other items above reveals the Samet has not disclosed a
financial conflict of interest which could have compro-
mised his objectivity on ETS. This imbalance further sug-
gests that the attacks on my research have nothing to do
with a principled concern about conflicts of interest, but
are purely a matter of not liking the results.
The article, "smoke out!", in the Spring 2003 issue of Johns
Hopkins Public Health, "The Magazine of the Johns Hop-
kins Bloomberg School of Public Health" [112] reveals
that, "After three years of preparation, Samet testified in
the landmark 1998 Minnesota tobacco trial that smoking
causes certain diseases like lung cancer" and that Samet
was "working on the federal government's $289 billion
lawsuit that accuses tobacco companies of 50 years of
deceptive marketing," which is the USDOJ lawsuit dis-
cussed above. Later, the article stated "In March, the Flight
Attendant Medical Research Institute honored Samet with
the '...Dr. William Cahan Distinguished Professor' Award
and $600,000 over 3 years to combat tobacco-related dis-
ease."
According to the Flight Attendant Medical Research Insti-
tute (FAMRI) website, the 'Dr. William Cahan Distin-
guished Professor' award to Samet during 2003–2006 was
"made in recognition of the recipients' ongoing work in
combating the diseases caused by exposure to second
hand tobacco smoke" [113]. In addition, Samet has a
prominent role in the current multi-million dollar Johns
Hopkins FAMRI Center of Excellence [114]. This CenterEpidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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was established in 2005 and currently has 30 FAMRI-
funded research projects on "diseases and medical condi-
tions caused from exposure to tobacco smoke," including
one by Samet on "Reducing the Risks of Secondhand
Tobacco Smoke Globally" [113].
FAMRI is a foundation established as a result of an Octo-
ber 1991 Class Action suit filed in Miami's Dade County
Circuit Court in Florida, known as Broin v. Philip Morris
[116]. This suit was filed against the tobacco industry on
behalf of flight attendants who sought damages for dis-
eases and deaths allegedly caused by their exposure to sec-
ond hand tobacco smoke in airline cabins [117]. A
settlement was reached in October 1997 between the
plaintiffs and four tobacco companies. The Settlement
Agreement included the establishment of a not-for-profit
medical research foundation with funding by the tobacco
industry of $300 million. The Foundation was to have no
tobacco company involvement, other than funding. The
purpose of the foundation was "to sponsor scientific
research with respect to the early detection and cure of dis-
eases associated with cigarette smoking" [118]. FAMRI, as
it was actually established, has a distinctly different mis-
sion, which is "to sponsor scientific and medical research
for the early detection, prevention, treatment and cure of
diseases and medical conditions caused from exposure to
tobacco smoke." [117]. Since FAMRI's mission statement
assumes that diseases like lung cancer and CHD are
caused by "exposure to tobacco smoke," this funding
source may have influenced Samet's decisions about
which epidemiologic studies he chooses to believe and
which ones he chooses to ignore, and thus should have
been disclosed. As noted in an August 23, 2006 JAMA edi-
torial, in published articles it is important "that readers
are aware of the authors' financial relationships and
potential conflicts of interest so that these readers can
interpret the article in light of that information" [119].
Jonathan M. Samet, M.D., and the 1992 EPA Report
One might wonder how omissions, distortions, and exag-
gerations like those pointed out above could occur in a
document as important as a Surgeon General's Report on
ETS. To better understand this phenomena one must real-
ize that Samet has dealt with the ETS issue in this manner
for many years. In particular, he played a major role in the
epidemiologic analysis for the December 1992 report on
Health Effects of Passive Smoking: Lung Cancer and Other
Disorders: The Report of the United States Environmental Pro-
tection Agency [120]. This EPA report classified ETS as a
Group A human carcinogen, which causes about 3,000
lung cancer deaths per year in the U.S. The findings from
this report were used in the Broin v. Philip Morris litigation
described above.
The epidemiologic methodology and conclusions of the
EPA report have been severely criticized. One of the harsh-
est critiques is the 92-page Decision issued by Federal
Judge William L. Osteen on July 17, 1998, which over-
turned the report in the U.S. District Court [121]. For
instance, in his conclusion Judge Osteen wrote: "In con-
ducting the Assessment, EPA deemed it biologically plau-
sible that ETS was a carcinogen. EPA's theory was
premised on the similarities between MS [mainstream
smoke], SS [sidestream smoke], and ETS. In other chap-
ters, the Agency used MS and ETS dissimilarities to justify
methodology. Recognizing problems, EPA attempted to
confirm the theory with epidemiologic studies. After
choosing a portion of the studies, EPA did not find a sta-
tistically significant association. EPA then claimed the
bioplausibility theory, renominated the a priori hypothe-
sis, justified a more lenient methodology. With a new
methodology, EPA demonstrated from the 88 selected
studies a very low relative risk for lung cancer based on
ETS exposure. Based on its original theory and the weak
evidence of association, EPA concluded the evidence
showed a causal relationship between cancer and ETS. The
administrative record contains glaring deficiencies. . . ."
In order to more fully understand the EPA report and its
inherent flaws, one must read the complete Osteen deci-
sion [121], as well as the books Passive Smoke: The EPA's
Betrayal of Science and Policy by Drs. Gio B. Gori and John
C. Luik [122], Ashes to Ashes: America's Hundred-Year Ciga-
rette War, the Public Health, and the Unabashed Triumph of
Philip Morris by Richard Kluger [123], For Your Own Good:
The Anti-Smoking Crusade and the Tyranny of Public Health
by Jacob Sullum [124], and the Brill's Content magazine
article "Warning: Secondhand Smoke May NOT Kill You"
by Nicholas Varchaver [125]. Finally, one must read the
January 28, 1993 Investors' Business Daily article "Is EPA
Blowing Its Own Smoke? How Much Science Is Behind Its
Tobacco Finding?" by Michael Fumento, who stimulated
my own interest in the ETS issue [126].
2006 Congress of Epidemiology and Trofim Denisovich 
Lysenko Analogy
In order to explain the phenomenon that has made this
defense of my epidemiologic research necessary, Geoffrey
Kabat, Sheldon Ungar, and I presented a symposium enti-
tled "Reassessment of the Long-term Mortality Risks of
Active and Passive Smoking" at the 2nd North American
Congress of Epidemiology in Seattle, Washington on June
24, 2006 [127]. We described major misrepresentations
that are currently occurring with regard to the epidemiol-
ogy of both active and passive smoking, as well as the
silencing of science associated with this area of epidemiol-
ogy. I presented the rationale for the symposium based on
the fact that important epidemiologic findings have been
ignored or mischaracterized in prior assessments. Then IEpidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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presented evidence that the adverse effects of active smok-
ing on mortality are less reversible by cessation than gen-
erally believed, based on randomized controlled trials
involving smoking cessation and "natural experiments"
involving the CA CPS I cohort and several other cohorts
[31,128,129]. Kabat presented evidence that the relation-
ship between passive smoking and mortality is weaker
than generally believed, particularly within the United
States, based on our two recent ETS papers [1,39]. Ungar
described the "silencing of science" phenomenon with
regard to our May 17, 2003 BMJ  paper that he docu-
mented and described in his 2005 paper [27].
In this symposium we addressed several important issues:
1) the implications of our reassessment for the relative
dangers of active and passive smoking; 2) the way in
which ideological and political agendas have influenced
the interpretation of epidemiologic evidence; and 3) the
importance of separating non-scientific agendas from
objective assessment of evidence. We made the case that:
1) all epidemiologic findings must be evaluated in a fair
and consistent manner in order to obtain an accurate
assessment of the mortality risks of active and passive
smoking; 2) epidemiologic findings must be judged on
their merits and not on extraneous factors; and 3) addi-
tional epidemiologic research in this area needs to be con-
ducted free of partisanship. Our complete presentations
are available on the Scientific Integrity Institute website
[130], and they include our PowerPoint slides and the
audio files for our lectures.
It is quite informative to compare our Symposium with
the June 23, 2006 lecture "Using Epidemiologic Evidence
to Advance Health: Dealing with Critics and Criticisms"
given by Samet at the same Congress of Epidemiology
[131]. Samet discussed the use of epidemiologic evidence
in public health policy making with regard to the environ-
mental epidemiology issues in which he has been
involved. In particular, he discussed the epidemiologic
evidence on the relationship between passive smoking
and lung cancer just four days before the June 27, 2006
release of the Surgeon General's Report on involuntary
smoking for which he was Senior Scientific Editor [79].
He talked about the criticism of weak epidemiologic rela-
tionships, such as those described in major documents
like the 2006 Surgeon General's Report. But he failed to
mention that much of this criticism is due to the fact that
he has attempted to turn weak and inconsistent observa-
tional epidemiologic evidence into an undisputed causal
relationship. He talked about how critics raise epidemio-
logic issues like confounding and bias, but he failed to
acknowledge his own biased presentation of the evidence,
including omitting my BMJ paper from the report and fail-
ing to acknowledge that the U.S. evidence is weaker than
the evidence outside of the U.S.
Also, it is quite telling how Samet dismissed critics of the
causal relationship between passive smoking and lung
cancer by classifying them as "stakeholders" linked with
the "tobacco industry." He implied that it is not necessary
to address the merits of their criticisms simply because
they are stakeholders in decisions related to passive smok-
ing. However, he failed to disclose his own financial inter-
ests that surely put him in the stakeholder category. He
certainly never mentions that his FAMRI money originates
from the tobacco industry, making it remarkably similar
to my CIAR funding. Samet's lecture provides insight into
his thought processes and the ways in which he manipu-
lates evidence to fit his vision of an epidemiologic rela-
tionship with public policy implications. The transcript of
a key portion of his lecture is available [132], as is the
audio file [133].
We concluded our Symposium by drawing an analogy
between the current situation involving ETS epidemiology
in the United States and the historical situation involving
agronomist Trofim Denisovich Lysenko and plant genet-
ics in the Soviet Union during the period of 1927–1962
[2]. While it is common to invoke George Orwell or
Joseph McCarthy in discussions like this, I believe the les-
sons from the admittedly more extreme Lysenko case are
more analogous and informative. Although ETS epidemi-
ologic evidence has never been conclusive, several major
reports have been issued with definitive conclusions
about a "causal relationship" between ETS and mortality.
All major U.S. government and private health agencies
have declared that a causal relationship exists and these
organizations have created "a regime of truth that cannot
be intelligibly questioned." These organizations then use
any means necessary to enforce this "regime of truth."
Since the publication of the influential null findings in my
BMJ paper, which contradict the "regime of truth," I have
been subjected to a massive ad hominem attack, my career
has been threatened, and my paper has been dismissed
because of its politically incorrect findings. In addition, I
was inserted into a massive lawsuit by my own govern-
ment in a manner that makes it appear that I have com-
mitted "scientific fraud" and have been engaged in
racketeering with the tobacco industry. There also has
been the attempt to force the University of California to
ban the tobacco industry funding that I have used and to
restrict future research in the areas of tobacco-related dis-
eases that I have been investigating.
Lysenko used his influence and backing by the Soviet gov-
ernment to create a "regime of truth" and to stop others'
research in order to promote scientifically invalid "vernal-
ization" and Lamarckian plant genetics. He was also suc-
cessful in attacking and destroying his critics, like Nicolai
Vavilov, who espoused proper Mendelian plant genetics.
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crop yields were low, Soviet agriculture regressed, and
Soviet citizens suffered greatly and many faced starvation.
During this same period, proper plant genetics were devel-
oped and implemented in the U.S. and this resulted in the
greatly increased crop yields that have made U.S. food
production so incredibly successful. The entire saga of
"Lysenko pseudoscience" has been extensively described
in websites about Lysenko [134], journal articles [2,135],
and books [136-138].
Prominent U.S. epidemiologists and activists are wielding
governmental influence to distort the epidemiology of
both active and passive smoking in the U.S. and are con-
tributing to a Lysenko-like research environment where it
is virtually impossible to conduct research that produces
politically incorrect findings, such as, those in my BMJ
paper. Much additional research is needed because the
primary tobacco-related disease, lung cancer, still causes
160,000 deaths per year in the U.S. and will not go away
any time soon. This Lysenko-like research environment
needs to end and epidemiologists must be free to conduct
additional research on tobacco-related diseases with a
variety of funding sources without fear of the kind of
attacks that I have experienced.
A Challenge to ACS and Michael J. Thun, M.D
Some of the controversy about the relation of ETS and
tobacco-related mortality in the largest U.S. observational
epidemiologic studies could be settled if Thun fully, fairly,
and transparently analyses the CPS I and CPS II cohort
data that the ACS currently possesses. Because of their size
and length of mortality follow-up, these two cohorts con-
tain the vast majority of the potentially available U.S. evi-
dence on ETS, and are already the basis for important U.S.
evidence on active smoking. Given the epidemiologic
expertise of Thun and the availability of the appropriate
CPS I and CPS II data, such an analysis could be con-
ducted in a matter of weeks. In the interest of better under-
standing cancer etiology, the ACS should fully analyze
these important data. I have provided sample Tables 3, 4,
5, 6 and 7 so that Thun can present results that are directly
comparable to those presented in my BMJ paper [1].
In addition, Thun should analyze the CPS II cohort as a
"natural experiment" of smoking cessation and mortality
trends in a manner similar to what I have done. Such an
analysis would test my hypothesis, based on analysis of
the CA CPS I and three other U.S. cohorts, that the long-
term adverse mortality effects of active smoking are more
dangerous than generally believed because they are less
reversible by cessation than generally believed
[31,128,129]. The ACS owes it to the over two million
Americans who are subjects in the CPS I and CPS II
cohorts, as well as to those Americans who support the
ACS, to produce epidemiologic findings that accurately
and completely describe the mortality risks of active and
passive smoking in their data.
In order to determine if a full analysis of ETS and mortal-
ity in the CPS II cohort supports the analysis of ETS and
mortality in the CA CPS I cohort presented in my BMJ
paper, I sent Thun a June 21, 2007 email request that he
complete Tables 5, 6 and 7. Thun replied with a June 26,
2007 letter in which he gave several reasons why he would
not complete Tables 5, 6 and 7. He stated "In summary, I
do not believe that the analyses you request in CPS-II
would produce scientifically meaningful results" [139].
He indicated no willingness to do further CPS II analyses
of any kind, even analyses of the relationship of ETS to
mortality during the past fifteen years. This is the latest
evidence supporting the extensive "silencing of science"
phenomena that currently exists with regard to ETS epide-
miology in the U.S.
To illustrate the existing bias in the release of ACS results,
it is quite informative to note the response by Thun to the
September 26, 1994 letter that he received from Glantz
[140], regarding the CPS II analyses that LeVois and
Layard conducted in 1994 and published in 1995 [40].
Thun sent Glantz a detailed November 4, 1994 letter
which included preliminary CPS II analyses and criticisms
and described plans to do further CPS II analyses [141].
Responses to Thun's CPS II analyses and criticisms were
then made by LeVois [142] and Layard [143]. All of this
correspondence and commentary reinforces the continu-
ing need for a full and objective analysis of the CPS I and
CPS II data possessed by ACS.
Conclusion
It is very disturbing that a major health organization like
the ACS has made false and misleading statements about
me and my May 17, 2003 BMJ paper for over four years. It
is further disturbing that prominent individuals like
Thun, Samet, and Glantz have continued to attack the
findings in the BMJ paper, even though I have presented
extensive evidence that supports the validity of these find-
ings. In addition, it is reprehensible that the BMJ paper
was inserted in the USDOJ RICO lawsuit and omitted
from the 2006 Surgeon General's Report. These actions
must be kept in mind when evaluating the honesty, integ-
rity, and objectivity of those responsible.
These criticisms may sound personally defensive, and
indeed when one is so personally attacked, some personal
defense is necessary. But this is also a defense against epi-
demiology becoming "Lysenko pseudoscience," where
the validity of methods and studies is based merely on
those results that are preferred by influential advocates
and researchers and contrary results are discredited using
the tactics of Lysenko. Epidemiologic science is not inher-E
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Table 3: Level of spousal smoking related to deaths from lung cancer and coronary heart disease among never smokers in California CPS I cohort as of 1959. Relative risk (RR 
with 95% CI) comparing persons with each level of exposure to those without exposure. Proportional hazards linear model (PHREG) is used and RR is adjusted for age at 
entry. Results shown are from Tables 7 and 8 of 2003 BMJ paper [1]. See note below.*
Lung cancer (ICD7 = 162–3, ICD8&9 = 162) Coronary heart disease(ICD7 = 420, ICD8&9 = 410–4)
1 Jan 60–30 Sep 72 1 Jan 60–31 Dec 98 1 Jan 60–30 Dec 72 1 Jan 60–31 Dec 98
Spousal smoking (ETS index level) as of 1959 Subjects Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI)
nn,nnn nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx)
Males
Never (1) 7,458 1.00 65 1.00 1,860 1.00
Former (2) 624 5 0.92 (0.37–2.30) 126 0.94 (0.78–1.12)
Current
1–9 cpd (3) 392 81 0.97 (0.78–1.21)
10–19' cpd(4) 513 99 0.86 (0.70–1.05)
20 cpd (5) 458 81 0.92 (0.74–1.15)
21–39 cpd (6) 129 27 1.16 (0.79–1.69)
40+ cpd (7) 45 13 1.29 (0.75–2.22)
Current – total 1,537 9 0.69 (0.34–1.39) 301 0.94 (0.83–1.07)
Ever 2,161 14 0.75 (0.42–1.35) 427 0.94 (0.85–1.05)
Females
Never (1) 7,399 1.00 51 1.00 1.00 1,053 1.00
Former (2) 6,858 51 1.08 (0.73–1.60) 1,059 1.02 (0.93–1.11)
Current
Pipe/cigar (3) 2,691 389 0.99 (0.88–1.11)
1–9 cpd (4) 1,102 183 1.13 (0.97–1.33)
10–19 cpd (5) 2,117 310 1.03 (0.91–1.17)
20 cpd (6) 3,288 412 1.04 (0.92–1.16)
21–39 cpd (7) 1,646 167 0.95 (0.80–1.12)
40+ cpd (8) 841 72 0.83 (0.65–1.06)
Current – total 11,685 75 0.93 (0.65–1.33) 1,533 1.01 (0.93–1.09)
Ever 18,543 126 0.99 (0.72–1.37) 2,592 1.01 (0.94–1.08)
*Tables C–G should be completed by Michael J. Thun, M.D., of the ACS to fully present results on ETS and lung cancer and coronary heart disease mortality in the CPS I cohort during 1960–
1972 and in the CPS II cohort during 1982–1998 in a format that is the same as that used for the 1960–1998 CA CPS I results in the 2003 BMJ paper (1), some of which are shown in Table C.E
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Table 4: Level of spousal smoking related to deaths from lung cancer and coronary heart disease among never smokers in 25-state CPS I cohort as of 1959. Relative 
risk (RR with 95% CI) comparing persons with each level of exposure to those without exposure. Proportional hazards linear model (PHREG) is used and RR is 
adjusted for age at entry.
Lung cancer (ICD7 = 162–3, ICD8 = 162) Coronary heart disease (ICD7 = 420, ICD8 = 410–4).
1 Jan 60–31 Dec 65 1 Jan 60–30 Sep 72 1 Jan 60–31 Dec 65 1 Jan 60–30 Sep 72
Spousal smoking (ETS index level) as of 1959 Subjects Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI)
nn,nnn nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx)
Males
N e v e r  ( 1 ) 1 . 0 01 . 0 01 . 0 01 . 0 0
Former (2)
Current
1–9 cpd (3)
10–19 cpd(4)
20 cpd (5)
21–39 cpd (6)
40+ cpd (7)
Current – total
Ever
Females
N e v e r  ( 1 ) 1 . 0 01 . 0 01 . 0 01 . 0 0
Former (2)
Current
Pipe/cigar (3)
1–9 cpd (4)
10–19 cpd (5)
20 cpd (6)
21–39 cpd (7)
40+ cpd (8)
Current – total
EverE
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Table 5: Level of spousal smoking related to deaths from lung cancer and coronary heart disease among never smokers in CPS II cohort as of 1982. Relative risk (RR with 
95% CI) comparing persons with each level of exposure to those without exposure. Proportional hazards linear model (PHREG) is used and RR is adjusted for age at 
entry.
Lung cancer (ICD9 = 162) Coronary heart disease (ICD9 = 410–4)
1 Sep 82–31 Dec 89 1 Sep 82–31 Dec 98 1 Sep 82–31 Dec 89 1 Sep 82–31 Dec 98
Spousal smoking (ETS index level) as of 1982 Subjects Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI)
nn,nnn nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx)
Males
N e v e r  ( 1 ) 1 . 0 01 . 0 01 . 0 01 . 0 0
Former (2)
Current
1–9 cpd (3)
10–19 cpd(4)
20 cpd (5)
21–39 cpd (6)
40+ cpd (7)
Current – total
Ever
Females
N e v e r  ( 1 ) 1 . 0 01 . 0 01 . 0 01 . 0 0
Former (2)
Current
Pipe/cigar (3)
1–9 cpd (4)
10–19 cpd (5)
20 cpd (6)
21–39 cpd (7)
40+ cpd (8)
Current – total
EverE
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Table 6: Total self-reported hours of ETS exposure per day related to deaths from lung cancer and coronary heart disease among all never smokers in CPS II cohort with data on self-reported 
ETS exposure as of 1982. Relative risk (RR with 95% CI) comparing persons with each level of exposure to those without exposure. Proportional hazards linear model (PHREG) is used and 
adjusted for age at entry.
Lung cancer (ICD9 = 162) Coronary heart disease (ICD9 = 410–4)
1 Sep 82–31 Dec 89 1 Sep 82–31 Dec 98 1 Sep 82–31 Dec 89 1 Sep 82–31 Dec 98
Total daily hours of ETS exposure as of 1982 Subjects Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI) Deaths Age-adjusted RR (95% CI)
nn,nnn nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx) nnn x.xx (x.xx-x.xx)
Males
0 hours 1.00 1.00 1.00 1.00
1
2
3
4
5
6
7
8+
Current total (1+)
Females
0 hours 1.00 1.00 1.00 1.00
1
2
3
4
5
6
7
8+
Current total (1+)E
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Table 7: 1982 level of spousal smoking related to total self-reported ETS exposure among never smokers in 1982 CPS II cohort and 1992 CPS II Nutrition cohort.
Percent distribution of 1982 total daily hours of ETS exposure Percent distribution of 1992 total weekly hours of ETS exposure
Spousal smoking as of 1982 1982 subjects 0 1 2 3–7 8+ 1992 subjects 0 1–7 8–14 15–49 50+
Males
Never (1)
Former (2)
Current
1–9 cpd (3)
10–19 cpd(4)
20 cpd (5)
21–39 cpd (6)
40+ cpd (7)
Current – total
Ever
Females
Never (1)
Former (2)
Current
Pipe/cigar (3)
1–9 cpd (4)
10–19 cpd (5)
20 cpd (6)
21–39 cpd (7)
40+ cpd (8)
Current – total
EverEpidemiologic Perspectives & Innovations 2007, 4:11 http://www.epi-perspectives.com/content/4/1/11
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ently pseudoscience, of course, but the process that has
led to many current claims about ETS is.
Hopefully, epidemiology can continue as a field in which
all legitimate research findings can be published and
objectively evaluated, including those findings considered
to be controversial. However, this will happen only if
advocacy organizations like the ACS and activists like
Glantz refrain from unethically smearing honest scientists
and putting out false and misleading statements. In addi-
tion, epidemiologists like Thun must honestly analyze all
the epidemiologic evidence that they possess and fully
report their results, and epidemiologists like Samet must
not omit important and accurate research findings from a
major document such as the Surgeon General's Report.
Such omissions and actions have seriously distorted the
evidence on the health effects of ETS exposure, particu-
larly within the US.
Hopefully, this entire episode will help prevent similar
episodes in the future. Furthermore, this episode will be
particularly valuable if it eventually leads to a full and
objective analysis of the important epidemiologic evi-
dence that the ACS possesses on both active and passive
smoking. In the meantime, epidemiologists and others
interested in a full assessment of the available epidemio-
logic evidence on the health effects of ETS should carefully
read and study this document and all the references and
tables that are included in it.
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